Markets:

Overview

News

Currencies

International

Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

94.38 -28.58 (-23.24%)

Streaming Delayed Price Updated: 1:42 PM EDT, Jun 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

Via The Motley Fool

Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump ↗

February 06, 2026

Focused on targeted cancer therapies, this biotech firm reported a notable insider sale amid a year of extraordinary stock performance.

Via The Motley Fool

Topics Regulatory Compliance

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

January 08, 2026

From Equity Insider

Via GlobeNewswire

The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens

January 02, 2026

As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In ↗

December 02, 2025

Via The Motley Fool

3 Stocks You’ll Wish You Bought Before 2026 ↗

December 03, 2025

Via MarketBeat

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results ↗

November 28, 2025

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results ↗

November 27, 2025

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Via The Motley Fool

Topics Regulatory Compliance

GEO Shares Down 44% as Fund Sells $9 Million in Stock Amid ICE Allegations and Softer Outlook ↗

November 27, 2025

GEO’s latest quarter shows a company pulling in record contracts while wrestling with litigation and cooling earnings guidance—here’s what investors need to know.

Via The Motley Fool

Topics Immigration Regulatory Compliance

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Exploring Celcuity's Earnings Expectations ↗

November 11, 2025

Via Benzinga

Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy Application ↗

November 17, 2025

FDA accepts NDA for Celcuity's advanced breast cancer therapy. Analyst downgrades stock due to high valuation. Next catalyst is topline data.

Via Benzinga

CELCUITY INC (NASDAQ:CELC) Stock Surges 70% in a Month Following Q3 Earnings Beat and Positive Clinical Data ↗

November 12, 2025

Celcuity stock surges after a Q3 earnings beat and positive clinical data for its lead drug candidate, gedatolisib.

Via Chartmill

Topics Earnings

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗

November 05, 2025

The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%.

Via Investor's Business Daily

These stocks are moving in today's session ↗

October 20, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 20, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗

October 20, 2025

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Gapping stocks in Monday's session ↗

October 20, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Topics Artificial Intelligence

Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results ↗

October 20, 2025

The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients.

Via Investor's Business Daily

Topics Government

Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results ↗

October 20, 2025

Via Benzinga

Topics Stocks

These stocks are moving in today's pre-market session ↗

October 20, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

October 20, 2025

Via Benzinga

Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

October 06, 2025

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END

Via FinancialNewsMedia

Celcuity Q2 Results Highlight Cash Surge ↗

August 14, 2025

Via The Motley Fool

Celcuity (CELC) Q2 2025 Earnings Call Transcript ↗

August 14, 2025

Via The Motley Fool

Topics Earnings

Celcuity Expenses Jump 81 Percent ↗

August 14, 2025

Via The Motley Fool

CELCUITY INC (NASDAQ:CELC) Reports Q2 2025 Earnings Miss Amid Clinical Progress in Gedatolisib Trials ↗

August 14, 2025

Celcuity (CELC) reported Q2 2025 results with a wider-than-expected EPS loss but revenue in line. Clinical progress in breast cancer trials drives investor optimism despite financial misses.

Via Chartmill

Topics Earnings

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.